These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12469179)

  • 1. Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review).
    Pathak SK; Sharma RA; Mellon JK
    Int J Oncol; 2003 Jan; 22(1):5-13. PubMed ID: 12469179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of prostate cancer: agents and study designs.
    Thompson IM
    J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nutrition and pharmacological treatment for prevention of prostate cancer].
    Segev Y; Nativ O
    Harefuah; 2006 Jan; 145(1):47-51, 76-7. PubMed ID: 16450727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice.
    Canby-Hagino ED; Thompson IM
    Nat Clin Pract Oncol; 2005 May; 2(5):255-61. PubMed ID: 16264961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of prostate cancer.
    Stephenson AJ; Abouassaly R; Klein EA
    Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.
    Mohanty NK; Saxena S; Singh UP; Goyal NK; Arora RP
    Urol Oncol; 2005; 23(6):383-5. PubMed ID: 16301113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of prostate cancer through dietary agents: progress and promise.
    Syed DN; Khan N; Afaq F; Mukhtar H
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2193-203. PubMed ID: 18006906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer chemoprevention.
    Sandhu GS; Nepple KG; Tanagho YS; Andriole GL
    Semin Oncol; 2013 Jun; 40(3):276-85. PubMed ID: 23806493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target populations and strategies for chemoprevention trials of prostate cancer.
    Bostwick DG
    J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
    Fujimoto N; Chang C; Nomura M; Matsumoto T
    Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer chemoprevention: current status and future prospects.
    Gupta S
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lycopene in the prevention of prostate cancer.
    Dahan K; Fennal M; Kumar NB
    J Soc Integr Oncol; 2008; 6(1):29-36. PubMed ID: 18302908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
    Marshall JR
    IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cells exposed to lycopene in vitro liberate lycopene-enriched exosomes.
    Goyal A; Delves GH; Chopra M; Lwaleed BA; Cooper AJ
    BJU Int; 2006 Oct; 98(4):907-11. PubMed ID: 16978292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of diet on prostate cancer: a review.
    Sonn GA; Aronson W; Litwin MS
    Prostate Cancer Prostatic Dis; 2005; 8(4):304-10. PubMed ID: 16130015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
    Roehrborn CG; Lotan Y; Tubaro A; de Nunzio C
    Eur Urol; 2006 Feb; 49(2):396-400. PubMed ID: 16455190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.